Opendata, web and dolomites

NO-GO SIGNED

NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NO-GO project word cloud

Explore the words cloud of the NO-GO project. It provides you a very rough idea of what is the project "NO-GO" about.

life    anxiety    doctors    sustainable    urinary    age    prescription    people    selling    oab    profits    standards    prepared    psychological    seize    archangelica    saga    improvement    cultivating    effect    benefit    fine    efficiency    internalize    social    relaxing    gmp    interactions    minimizing    population    worldwide    angelica    treatments    plant    healthcare    depression    108    too    health    roi    symptoms    day    claims    gt    30    obtain    rates    500    icelandic    multiple    business    75    characterization    vitro    2021    prevalence    million    iceland    normal    efsa    over    launched    patients    bodies    impaired    complying    tune    natural    nocturia    validation    expensive    preserving    21    capacity    active    starting    10    safety    precursor    validated    formulation    demonstrating    america    clinically    regulate    small    clinical    save    leaves    recommend    mass    vivo    north    embarrassment    natura    pharmacological    66    create    drugs    urgency    sagapro    trial    landscape    expansion    jobs    bladder    extend    2005    syndrome    80    iso    market    made    opportunity    16    ecosystem    dropout    performed   

Project "NO-GO" data sheet

The following table provides information about the project.

Coordinator
SAGANATURA EHF 

Organization address
address: SUDURHELLU 8
city: HAFNARFJORDUR
postcode: 221
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Total cost 2˙232˙470 €
 EC max contribution 1˙562˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGANATURA EHF IS (HAFNARFJORDUR) coordinator 1˙562˙729.00

Map

 Project objective

Over Active Bladder (OAB) is a syndrome characterized by several urinary symptoms, like urgency and nocturia. Prevalence is >10% of the population, 500 million people worldwide, and increases with age (>30% over 75 years old). OAB has psychological consequences such as embarrassment, impaired social interactions, depression and anxiety. Current pharmacological treatments for OAB are associated with multiple side effects and 80% dropout rates within 1 year. At Saga Natura we have developed NO-GO, a natural product for improving OAB symptoms, made from the leaves of the Icelandic plant Angelica archangelica. NO-GO’s precursor SagaPro was launched on the market in 2005, becoming Iceland’s top-selling non-prescription urinary product. We have performed in vivo and in vitro characterization of SagaPro’s bladder relaxing effect and we have clinically validated SagaPro in a small-scale clinical trial on 66 OAB patients, demonstrating it’s efficiency and safety. In Phase 2 we want to fine-tune our formulation, increase and internalize our production capacity complying with ISO and GMP standards and extend our clinical validation. We will also regulate NO-GO through the EFSA to obtain health claims. This way we will be prepared for our product’s mass expansion in Europe and in North America starting in 2021. This project will create 21 new jobs and profits of €108 Million with ROI of 16.6 after 5 years on the market. End-users will benefit from improvement of symptoms, no side effects, and ability to lead a normal every day life. Doctors will be able to recommend NO-GO to their OAB patients, a product with no side effects, and healthcare bodies will save costs on expensive OAB prescription drugs with too high dropout rates. Finally, with our sustainable approach for cultivating Angelica archangelica we will seize this business opportunity while also preserving the Icelandic landscape, using natural resources and minimizing the impact to the ecosystem.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-GO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-GO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More